BioLife Solutions Inc (BLFS) - Total Assets
Based on the latest financial reports, BioLife Solutions Inc (BLFS) holds total assets worth $447.49 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioLife Solutions Inc - Total Assets Trend (1988–2025)
This chart illustrates how BioLife Solutions Inc's total assets have evolved over time, based on quarterly financial data. Also see BioLife Solutions Inc (BLFS) market capitalisation for the company's overall valuation and market capitalisation.
BioLife Solutions Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
BioLife Solutions Inc's total assets of $447.49 Million consist of 33.7% current assets and 66.4% non-current assets. Review BioLife Solutions Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $7.95 Million | 2.0% |
| Inventory | $30.16 Million | 7.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.26 Million | 1.1% |
| Goodwill | $208.59 Million | 51.4% |
Asset Composition Trend (1988–2025)
This chart illustrates how BioLife Solutions Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of BioLife Solutions Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioLife Solutions Inc's current assets represent 33.7% of total assets in 2025, a decrease from 100.0% in 1988.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 80.0% in 1988.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 1988.
- Asset Diversification: The largest asset category is goodwill at 51.4% of total assets.
BioLife Solutions Inc Competitors by Total Assets
Key competitors of BioLife Solutions Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Shanghai Tofflon Science Tech
SHE:300171
|
China | CN¥13.30 Billion |
|
Autek China Inc
SHE:300595
|
China | CN¥6.40 Billion |
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
China | CN¥1.72 Billion |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.79 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.39 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
BioLife Solutions Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.69 | 4.43 | 3.65 |
| Quick Ratio | 7.14 | 3.45 | 2.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $121.25 Million | $97.12 Million | $94.71 Million |
BioLife Solutions Inc - Advanced Valuation Insights
This section examines the relationship between BioLife Solutions Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.12 |
| Latest Market Cap to Assets Ratio | 4.21 |
| Asset Growth Rate (YoY) | 1.6% |
| Total Assets | $405.88 Million |
| Market Capitalization | $1.71 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BioLife Solutions Inc's assets at a significant premium (4.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: BioLife Solutions Inc's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BioLife Solutions Inc (1988–2025)
The table below shows the annual total assets of BioLife Solutions Inc from 1988 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $405.88 Million | +1.60% |
| 2024-12-31 | $399.49 Million | -3.20% |
| 2023-12-31 | $412.71 Million | -8.33% |
| 2022-12-31 | $450.23 Million | -18.77% |
| 2021-12-31 | $554.29 Million | +136.04% |
| 2020-12-31 | $234.83 Million | +152.47% |
| 2019-12-31 | $93.01 Million | +104.57% |
| 2018-12-31 | $45.47 Million | +274.43% |
| 2017-12-31 | $12.14 Million | +53.19% |
| 2016-12-31 | $7.93 Million | -35.92% |
| 2015-12-31 | $12.37 Million | -23.04% |
| 2014-12-31 | $16.07 Million | +379.31% |
| 2013-12-31 | $3.35 Million | +5.79% |
| 2012-12-31 | $3.17 Million | +90.72% |
| 2011-12-31 | $1.66 Million | +26.96% |
| 2010-12-31 | $1.31 Million | -1.87% |
| 2009-12-31 | $1.33 Million | +13.95% |
| 2008-12-31 | $1.17 Million | +61.24% |
| 2007-12-31 | $726.02K | +29.55% |
| 2006-12-31 | $560.43K | +25.35% |
| 2005-12-31 | $447.11K | -46.34% |
| 2004-12-31 | $833.27K | -71.89% |
| 2003-12-31 | $2.96 Million | +844.38% |
| 2002-12-31 | $313.85K | -82.33% |
| 2001-12-31 | $1.78 Million | -55.46% |
| 2000-12-31 | $3.99 Million | +84.74% |
| 1999-12-31 | $2.16 Million | -20.84% |
| 1998-12-31 | $2.73 Million | -29.69% |
| 1997-12-31 | $3.88 Million | -35.83% |
| 1996-12-31 | $6.04 Million | -28.06% |
| 1995-12-31 | $8.40 Million | 0.00% |
| 1994-12-31 | $8.40 Million | -7.66% |
| 1993-12-31 | $9.10 Million | +8.33% |
| 1992-12-31 | $8.40 Million | -35.38% |
| 1991-12-31 | $13.00 Million | +132.14% |
| 1990-12-31 | $5.60 Million | +60.00% |
| 1989-12-31 | $3.50 Million | +600.00% |
| 1988-12-31 | $500.00K | -- |
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, inc… Read more